Skip to content
AwardedPOLGoods

Produkt leczniczy - Lisocabtagene Maraleucel

Published
Published 7 May 2026

Overview

The Institute of Hematology and Transfusion procured the medicinal product Lisocabtagene Maraleucel. The contract was awarded to Bristol-Myers Squibb Polska Sp. z o.o. and Urtica Sp.zo.o. for 7,788,960 PLN on 29 May 2026.

Key details

Country
POL
Status
Awarded
Category
Goods
Procedure
Direct
Published
7 May 2026
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
PLN 7,788,960
Award date
29 May 2026
Contract period
— → 24 May 2027
Winners
  • Bristol-Myers Squibb Polska Sp. z o.o.
  • Urtica Sp.zo.o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    26 June 2026

  2. Contract Notice

    7 May 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Produkt leczniczy - Lisocabtagene Maraleucel — won by Bristol-Myers Squibb Polska Sp. z o.o. +1 — Skim